Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating Impact of Azithromycin Mass Drug Administrations on All-cause Mortality and Antibiotic Resistance: Morbidity Study
Brief Summary: The long-term goal of this study is to more precisely define the role of mass azithromycin treatments as an intervention for reducing childhood morbidity and increasing growth, and for the potential selection of antibiotic resistance. The investigators propose a set of 3 cluster-randomized trials in Malawi, Niger, and Tanzania comparing communities randomized to oral azithromycin with those randomized to placebo. To assess the generalizability of the intervention, investigators will monitor for antibiotic resistance, which could potentially limit adoption of mass antibiotic treatments. The investigators will also assess several measures of infectious diseases. The investigators hypothesize that mass azithromycin treatments will reduce childhood morbidity and will be accompanied by an acceptable level of antibiotic resistance.


Options:
A: Arm Label: Biannual mass oral azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Biannual mass oral placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Biannual mass oral azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Biannual mass oral placebo
B: Arm Label: Azythromycin (APRIL) and Prednisolone (OCELOT); Type: EXPERIMENTAL; Interventions: Drug: Azithromycin, Drug: Prednisolone | Arm Label: Azythromycin (APRIL) and Placebo (OCELOT); Type: EXPERIMENTAL; Interventions: Drug: Azithromycin, Drug: Placebo Prednisolone | Arm Label: Placebo (APRIL) and Prednisolone (OCELOT); Type: EXPERIMENTAL; Interventions: Drug: Prednisolone, Other: Placebo Azithromycin | Arm Label: Placebo (APRIL) and Placebo (OCELOT); Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Azithromycin, Drug: Placebo Prednisolone | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azythromycin (APRIL) and Placebo (OCELOT), Azythromycin (APRIL) and Prednisolone (OCELOT) | Intervention Type: DRUG; Name: Prednisolone; Assigned to Arm(s): Azythromycin (APRIL) and Prednisolone (OCELOT), Placebo (APRIL) and Prednisolone (OCELOT) | Intervention Type: OTHER; Name: Placebo Azithromycin; Assigned to Arm(s): Placebo (APRIL) and Placebo (OCELOT), Placebo (APRIL) and Prednisolone (OCELOT) | Intervention Type: DRUG; Name: Placebo Prednisolone; Assigned to Arm(s): Azythromycin (APRIL) and Placebo (OCELOT), Placebo (APRIL) and Placebo (OCELOT)
C: Arm Label: Clarithromycin; Type: EXPERIMENTAL; Interventions: Drug: Clarithromycin, Drug: VCD induction therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: VCD induction therapy | Intervention Type: DRUG; Name: Clarithromycin; Assigned to Arm(s): Clarithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: VCD induction therapy; Assigned to Arm(s): Clarithromycin, Placebo
D: Arm Label: Azithromycin Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin Group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Group

Answer: A